1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

Xintela: Taking position for the next phase

• Encouraging interim results with XSTEM OA
• EQGen licensing deal signed regarding EQSTEM
• Our fair value amounts to SEK 1.49 per share

During the spring Xintela announced positive interim data from its phase I/IIa study with XSTEM in knee ostoearthritis. The company also signed a license and collaboration agreement wtih EQGen Biomedical regarding EQSTEM. Despite the advances, Xintela's financial situation remains challenging. The company reported cash holdings of MSEK 6.4 by the end of Q1. Most likely, the company will receive proceeds from the warrant TO3, the last exercise period is ongoing. If fully subscribed, TO3 could add MSEK 11. Xintela is also awaiting the upfront fee of MSEK 1 from EQGen.

Our model suggests a fair value of SEK 1.49 per share. The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2025-06-02, kl 15:20
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.